Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
1. PCRX settled litigations regarding Exparel patents with multiple pharmaceutical companies. 2. Settlement includes a license for limited generic entry beginning in early 2030. 3. Pacira’s fourth-quarter sales for Exparel increased 3% year-over-year to $147.7 million. 4. Analysts maintain 'Buy' ratings with price targets raised significantly after the news. 5. PCRX stock rose 16.8%, reflecting positive market sentiment on this announcement.